Plasma Concentration of Heat Shock Protein 27 and Risk of Cardiovascular Disease: A Prospective, Nested Case-Control Study

Abstract Background: Heat shock protein 27 (HSP27) has been hypothesized to be a potential biomarker of atherothrombosis. However, no prospective studies have yet been performed to investigate the association between HSP27 plasma concentration and incident cardiovascular events among initially healthy individuals. Methods: We evaluated plasma concentrations of HSP27 at baseline among 255 initially healthy participants in the Women’s Health Study who subsequently developed myocardial infarction, ischemic stroke, or cardiovascular death during a follow-up period of up to 5.9 years and among an equal number of women matched for age and smoking but who remained free of cardiovascular disease over the same time period. Results: Overall, HSP27 plasma concentrations were inversely associated with age (Spearman correlation coefficient r = −0.258, P <0.001), but not with other established cardiovascular risk factors. Conditional logistic regression analysis showed no significant association of baseline HSP27 plasma concentration with future cardiovascular disease; the odds ratio for upper vs lower tertile of HSP27 concentration at baseline was 0.99 (95% CI 0.62–1.57, P for trend = 0.99). Conclusion: In this prospective study of initially healthy women, baseline HSP27 plasma concentration was not associated with incident cardiovascular events.

Download Full-text

Abstract: P805 SERUM HEAT SHOCK PROTEIN 27 (HSP27) ANTIGEN AND IMMUNOGLOBULIN M (IGM) ANTIBODY LEVELS APPEAR TO BE RELATED TO THE PRESENCE OF INSULIN RESISTANCE AND CARDIOVASCULAR DISEASE (CVD)

Atherosclerosis Supplements ◽

10.1016/s1567-5688(09)70960-2 ◽

2009 ◽

Vol 10 (2) ◽

pp. e982

Author(s):

DF Pengiran Burut ◽

A Borai ◽

C Livingstone ◽

G Ferns

Keyword(s):

Insulin Resistance ◽

Cardiovascular Disease ◽

Heat Shock ◽

Heat Shock Protein ◽

Heat Shock Protein 27 ◽

Immunoglobulin M ◽

Igm Antibody ◽

Antibody Levels

Download Full-text

Heat shock protein 27: a potential biomarker of peritoneal metastasis in epithelial ovarian cancer?

Tumor Biology ◽

10.1007/s13277-013-1139-7 ◽

2013 ◽

Vol 35 (2) ◽

pp. 1051-1056 ◽

Cited By ~ 21

Author(s):

M. Zhao ◽

J. X. Ding ◽

K. Zeng ◽

J. Zhao ◽

F. Shen ◽

...

Keyword(s):

Ovarian Cancer ◽

Heat Shock ◽

Heat Shock Protein ◽

Epithelial Ovarian Cancer ◽

Peritoneal Metastasis ◽

Heat Shock Protein 27 ◽

Potential Biomarker

Download Full-text

Phosphorylated heat shock protein 27 as a potential biomarker to predict the role of chemotherapy-induced autophagy in osteosarcoma response to therapy

Oncotarget ◽

10.18632/oncotarget.20308 ◽

2017 ◽

Vol 9 (2) ◽

pp. 1602-1616 ◽

Cited By ~ 11

Author(s):

Janice M. Santiago-O’Farrill ◽

Eugenie S. Kleinerman ◽

Mario G. Hollomon ◽

Andrew Livingston ◽

Wei-Lien Wang ◽

...

Keyword(s):

Heat Shock ◽

Heat Shock Protein ◽

Heat Shock Protein 27 ◽

Response To Therapy ◽

Potential Biomarker

Download Full-text

Heat shock protein 27: a potential biomarker for colorectal carcinoma

World Chinese Journal of Digestology ◽

10.11569/wcjd.v18.i12.1237 ◽

2010 ◽

Vol 18 (12) ◽

pp. 1237

Author(s):

Wei-Jie Liu ◽

Huan-Long Qin ◽

Yan-Lei Ma ◽

Jia-Yuan Peng

Keyword(s):

Heat Shock ◽

Colorectal Carcinoma ◽

Heat Shock Protein ◽

Heat Shock Protein 27 ◽

Potential Biomarker

Download Full-text

Abstract 15859: Fibroblast Growth Factor 23 and Myocardial Infarction in the Boston Puerto Rican Health Study

Circulation ◽

10.1161/circ.142.suppl_3.15859 ◽

2020 ◽

Vol 142 (Suppl_3) ◽

Author(s):

Chinedu C Ochin ◽

Joseph Salami ◽

Emir Veledar ◽

Mahdi O Garelnabi ◽

Katherine L Tucker

Keyword(s):

Myocardial Infarction ◽

Cardiovascular Disease ◽

Plasma Concentration ◽

Puerto Rican ◽

Cardiovascular Events ◽

Cardiovascular Outcomes ◽

Health Study ◽

Cross Sectional ◽

Increased Risk ◽

Fgf 23

Background: FGF-23 is an endocrine regulator of phosphate metabolism as well as also a potent biomarker that mediates cardiovascular remodeling, with markedly elevated plasma concentration associated with the occurrence of morbid cardiovascular events such as myocardial infarction. This association usually indicates risk of developing further adverse cardiovascular events in individuals that are already susceptible to repeat morbid cardiovascular outcomes. This cross-sectional epidemiological study aims at investigating the risk association between FGF-23 and individuals in the 8 th year cohort of the Boston Puerto Rican Health Study (BPRHS) that have self-reported clinical cardiovascular disease in the form of myocardial infarction. Methods: FGF-23 plasma concentration was measured by ELISA in 496 participants of the fourth wave of the Boston Puerto Rican Health Study (BPRHS). Multivariate logistic regressions were used to analyze the cross-sectional association of plasma FGF-23 quartile distribution with self-reported clinical diagnosis of myocardial infarction (MI). Results: The crude model for the association between FGF-23 and MI showed increased risk across the 2 nd , 3 rd and 4 th quartiles, OR (95% CI); 1.27 (0.48-3.34), 1.13 (0.42-3.04), and 3.13 (1.33-7.33), respectively. The relationship with the highest vs lowest quartile remained significant after adjusting for age, sex and BMI, OR (95% CI); 2.91 (1.15-7.36). With further adjustment for diabetes, smoking, plasma total cholesterol, HDL cholesterol and triglycerides, results were attenuated, and the latter comparison was no longer statistically significant, OR (95% CI); 2.15 (0.79-5.79). The test for trend across the quartiles yielded a p value of 0.03. Conclusion: Within this population of older Puerto Rican adults, FGF-23 was not significantly associated with increased likelihood of self-reported history of myocardial infarction. Longitudinal studies, using clinical parameters that objectively measure the progression of cardiovascular disease are needed to assess the prognostic value of FGF-23 for future cardiovascular outcomes.

Download Full-text